Catalyst Calendar

Donzakimig - Atopic Dermatitis - Ph2a - Results

UCB Pipeline page (ucb.com/innovation/pipeline)

Tozorakimab - COPD - Ph3 - Topline (OBERON)

ClinicalTrials.gov NCT05166889 (PCD Jan 2026)

Sonesitatug - Gastric CLDN18.2+ - Ph3 - Topline

AZN JPM 2026 Presentation

Ultomiris - IgAN - Ph3 - Topline (ICAN)

AZN Q3 2025 Clinical Appendix (PCD Feb 2026)

Lunsumio + Polivy - DLBCL - FDA Approval

Roche SUNMO Phase 3 data positive

Imfinzi + Imjudo - Locoregional HCC - Ph3 - Topline

AZN JPM 2026 Presentation

Efzimfotase Alfa - HPP - Ph3 - Topline

AZN JPM 2026 Presentation

Imfinzi ± Imjudo - MIBC - Ph3 - Topline

AZN JPM 2026 Presentation

Ultomiris - HSCT-TMA - Ph3 - Topline

AZN Q3 2025 Clinical Appendix

Cevostamab - MM - Ph3 - Start (Cevolution)

Roche investor update 2025

Darzalex - MM - Bispecific Combo Data

Genmab JPM 2026 Presentation

Tagrisso + Orpathys - EGFRm NSCLC - Ph3 - Topline

AZN JPM 2026 Presentation

STACCATO Alprazolam - Seizures - Ph3 - Headline Results

UCB Pipeline page (ucb.com/innovation/pipeline)

Rybrevant - NSCLC - SC Formulation Data

Genmab JPM 2026 Presentation

Rinvoq - Vitiligo - FDA Approval

AbbVie Q4 2025 Earnings (news.abbvie.com)

Skyrizi - Psoriasis - H2H vs Deucravacitinib

AbbVie Q4 2025 Earnings (news.abbvie.com)

Rinvoq - GCA - FDA Approval

AbbVie Q4 2025 Earnings (news.abbvie.com)

Teliso-V - NSCLC - Accelerated Approval

AbbVie Q4 2025 Earnings (news.abbvie.com)

Epkinly - DLBCL - Ph3 - Topline (EPCORE DLBCL-4)

Genmab JPM 2026 Presentation

Rinvoq - Alopecia Areata - Ph3 - Data (UP-AA)

AbbVie Q4 2025 Earnings (news.abbvie.com)

Venclexta - HR-MDS - FDA Approval

AbbVie Q4 2025 Earnings (news.abbvie.com)

Rinvoq - HS - Ph3 - Data

AbbVie Q4 2025 Earnings (news.abbvie.com)

Pivekimab Sunirine - BPDCN - FDA Approval

AbbVie Q4 2025 Earnings (news.abbvie.com)

Datroway + Imfinzi - NSCLC - Ph3 - Topline (TROPION-Lung08)

ClinicalTrials.gov NCT05555732

Rinvoq - SLE - Ph3 - Data

AbbVie Q4 2025 Earnings (news.abbvie.com)

Eloralintide - Obesity - Ph2b - Topline

Lilly Q4 2025 Earnings

Pirtobrutinib - 1L MCL - FDA Filing

Lilly oncology pipeline updates

Galvokimig - Atopic Dermatitis - Ph2b - Start/Updates

UCB EADV 2025 PR, ucb.com Sep 2025

Aleniglipron - Obesity - FDA Type B EoP2 Meeting

ir.structuretx.com ACCESS PR Dec 8, 2025

Vyvgart - Ocular MG - Ph3 - Topline (ADAPT-OCULUS)

argenx Corporate Presentation Feb 2026

Claseprubart - gMG - Ph3 - Trial Initiation

NeurologyLive; Dianthus 2025 corporate updates

ISL/LEN - HIV Treatment - Ph3 - Topline (ISLEND-1/2)

Gilead Q4 2025 Earnings, JPM 2026

MariTide - Obesity - Ph2 Part 2 - Maintenance/Quarterly Dosing Data

Amgen JPM 2026 presentation, Q4 2025 earnings call

Dupixent - CSU - Ph3 Topline (LIBERTY-CSU CUPID)

REGN Q4 2025 earnings, ClinicalTrials.gov

EYLEA 2mg Biosimilar Competition Impact

FDA biosimilar approvals, REGN Q4 2025 earnings

Fenebrutinib - RMS - Ph3 - Topline (FENhance 1)

Roche PR Nov 10, 2025 (FENhance 2 positive)

Tirzepatide - MASH - Ph3 - Topline (SYNERGY-NASH)

Lilly pipeline disclosures

Giredestrant - 1L mBC - Ph3 - Topline (persevERA)

ClinicalTrials.gov NCT04546009

Datroway - TROP2 Biomarker-Directed - Ph3 - Start (TROPION-Lung17)

DSNKY PR Jan 13, 2026

Vyvgart - oMG - Ph3 - Topline (ADAPT-OCULUS)

ARGX corporate guidance; Wells Fargo Feb 4, 2026

Enhertu + Pertuzumab - 1L HER2+ mBC - FDA Approval (DESTINY-Breast09)

FDA Priority Review, daiichisankyo.com PDUFA date

PADCEV + Keytruda - MIBC - Japan sNDA Filed

astellas.com newsroom Jan 30, 2026

Retatrutide - Obesity/CVD - Ph3 - Topline (TRIUMPH-3)

ClinicalTrials.gov NCT05882045

AZN - FY 2025 Results & 2026 Guidance

astrazeneca.com/investor-relations (Financial Calendar)

ASND - FY 2025 Results

investors.ascendispharma.com JPM 2026 Presentation

SOBI - Capital Markets Day (Ambition 2030)

SOBI IR website, CMD invitation (sobi.com/investors)

UCB - FY 2025 Results & 2026 Guidance

ucb.com/investors (Financial Calendar)

TransCon CNP - Achondroplasia - FDA PDUFA

investors.ascendispharma.com PDUFA extension PR Nov 25, 2025

ASP3082 (Setidegrasib) - Pancreatic Cancer - Ph3 - Start

Astellas JPM 2026, AACR-NCI-EORTC 2025 data

Amycretin - Obesity - Ph3 - Start

NVO JPM 2026, Q4 2025 earnings call

Pluvicto - Pre-Chemo mCRPC - FDA Approval

Novartis PSMAfore PR, FDA filing 2025

Anito-cel - Multiple Myeloma - FDA Approval

Gilead JPM 2026, CEO statement

Repatha - Primary Prevention - VESALIUS-CV Subgroups at ACC

Amgen Q4 2025 earnings call, ACC 2026 schedule

Orforglipron - Obesity - FDA Approval

CEO statement Nov 6, 2025; NDA submitted Dec 18, 2025

VOYXACT - IgA Nephropathy - Ph3 - eGFR Confirmatory Data (VISIONARY)

Otsuka IR; FDA accelerated approval requirement; VISIONARY trial design

Baxdrostat - Hypertension - FDA Approval

AstraZeneca PR (astrazeneca.com), PDUFA Q2 2026

Datroway - 1L mTNBC (PD-L1 neg) - FDA Approval

AstraZeneca/Daiichi Sankyo PR Jan 2026

BIC/LEN - HIV Treatment - FDA Filing

Gilead ARTISTRY-2 PR (gilead.com)

GMAB - Merus Integration Update

Genmab JPM 2026 Presentation

Trodelvy - 1L NSCLC - Ph3 - Topline (EVOKE-03)

Gilead JPM 2026 (CMO Berger)

Pirtobrutinib - CLL - Ph3 - Full Data vs Imbruvica

Lilly Q4 2025 Earnings

Claseprubart - CIDP - Ph3 - Interim Responder Analysis (CAPTIVATE Part A, n=40)

Dianthus Q3 2025 earnings release; ClinicalTrials.gov NCT06858579

Dazodalibep - Sjogren's - Ph3 Data (2 studies)

Amgen Q4 2025 earnings, amgenpipeline.com

Pozdeutinurad - Progressive Gout - Ph3 - Topline (REDUCE-2)

SOBI Q4 2025 Report; Arthrosi acquisition press release

Zynlonta - R/R DLBCL 2L - Ph3 - Data (LOTIS-5)

SOBI Pipeline page; ClinicalTrials.gov

Beyfortus - RSV Royalty Revenue Trajectory (vs Enflonsia)

SOBI Q4 2025 Report; CDC RSVVaxView; Merck Enflonsia approval

Altuviiio - Hemophilia A Commercial Ramp (EU/Middle East)

SOBI Q4 2025 Report

Icotrokinra - Mod-sev PsO - FDA PDUFA Decision

JNJ press release July 21, 2025 — NDA submission; standard 10-month PDUFA timeline

DSNKY - 6th 5-Year Business Plan Briefing

daiichisankyo.com Q3 FY2025 Earnings announcement

Retatrutide - Obesity - Ph3 - Topline (TRIUMPH-1)

ClinicalTrials.gov NCT05929066

AMGN - Q1 2026 Earnings

Typical AMGN earnings cadence

REGN - Q1 2026 Earnings

Typical REGN earnings cadence

LLY - Q1 2026 Earnings

Lilly investor calendar

GILD - Q1 2026 Earnings

Gilead IR Calendar

BMRN - Q1 2026 Earnings

investors.biomarin.com (typical quarterly cadence)

Retatrutide - T2D - Ph3 - Topline (TRIUMPH-2)

ClinicalTrials.gov NCT05929079

SOBI - Q1 2026 Earnings

SOBI typical earnings calendar

NVO - Q1 2026 Earnings

novonordisk.com/investors/financial-calendar

NVS - Avidity Biosciences Acquisition Close

Novartis PR Jan 13, 2026

Sac-TMT + Keytruda - 1L NSCLC - Ph3 - Update (OptiTROP-Lung05)

Merck JPM 2026, OptiTROP-Lung05 results

I-DXd - SCLC - Ph3 - Clinical Hold Update (IDeate-Lung02)

FDA partial clinical hold Dec 2025, FierceBiotech

Aleniglipron - Obesity - Ph3 - Start

ir.structuretx.com ACCESS PR Dec 8, 2025

Amycretin - T2D - Ph3 - Start

NVO pipeline update Nov 2025

Entresto - Generic Competition Impact

Novartis Q4 2025 Earnings

Leqvio - Commercial Uptake Updates

Novartis Q4 2025 Earnings

Ozempic 25mg Tablets - T2D - FDA Filing

NVO pipeline, regulatory updates

Aleniglipron - ACCESS Full Data - Medical Meeting

ir.structuretx.com, typical development timeline

Winrevair - PAH - Label Expansion Data

Merck JPM 2026 Presentation

Gardasil - China Demand Update

Merck Q4 2025 Earnings

Evenity - Commercial Uptake (with Amgen)

UCB JPM 2026 Presentation

MRK - Business Development

Merck JPM 2026 (CEO Davis)

Fintepla - Commercial Updates

UCB JPM 2026 Presentation

Enhertu - Global Sales Trajectory

DSNKY Q3 FY2025 Earnings

Veozah - Commercial Uptake Updates

Astellas Q3 FY2025 Earnings

Livdelzi - PBC - Full Approval & EU

Gilead JPM 2026 Presentation

Xospata - Commercial Updates

Astellas Q3 FY2025 Earnings

PADCEV + Keytruda - Cis-Ineligible MIBC - EMA Approval

astellas.com newsroom, EMA CHMP review ongoing

Vyloy - Global Launch Trajectory

Astellas JPM 2026, Q3 FY2025 Earnings

Trodelvy - 1L mTNBC - FDA Approval

NEJM publication Jan 2026, Gilead PR

Bimzelx - Commercial Momentum Updates

UCB JPM 2026 Presentation

ASP2138 - Gastric Cancer - Ph1 - Updates

Astellas JPM 2026, ASCO GI 2026

ANPA-0073 - Muscle-Sparing Weight Loss - Ph2 Decision

ir.structuretx.com Q2 2025 Earnings

Lenacapavir PrEP - Global Rollout

Gilead JPM 2026 Presentation

225Ac-PSMA-617 - mCRPC - Ph3 - Start

Novartis JPM 2026 Presentation

Pelabresib - Myelofibrosis - EU Filing/Approval

Novartis Q4 2025 Earnings, FDA CRL

Sac-TMT - EGFR NSCLC - FDA Filing

Merck BTD PR, NEJM publication

Pelabresib - Myelofibrosis - Ph3 - Start (MANIFEST-3)

Novartis Q4 2025 Earnings

Scemblix - 1L CML - FDA Approval

Novartis ASC4FIRST PR, JPM 2026

ASP3082 - NSCLC - Registrational Study Preparation

Astellas JPM 2026, Oncology Pipeline Meeting Oct 2025

Cagrilintide - Obesity - Ph3 - Start (RENEW)

NVO pipeline overview, JPM 2026

Hepcludex - Chronic Hepatitis Delta - FDA Approval

Gilead Q4 2025 Earnings Presentation

Pelacarsen - Lp(a) CV Prevention - Ph3 - Topline (HORIZON)

ClinicalTrials.gov NCT04023552, Novartis JPM 2026

Rytelo - Lower-risk MDS - EU Country-by-Country Launch

SOBI Q4 2025 Report

Doptelet - Pediatric ITP + EU Expansion - Ongoing

SOBI Q4 2025 Report

Elecoglipron - Obesity/T2DM - Ph2b - Full Data (ADA 2026)

AZN Q4:25 earnings presentation (Feb 10, 2026); ADA Scientific Sessions June 5-8, 2026

NASP - Uncontrolled Gout - FDA PDUFA Decision

FDA PDUFA date per SOBI Q4 2025 Report

Gazyva - Membranous Nephropathy - Ph3 - Topline

Roche JPM 2026 Presentation

Datroway ± Tagrisso - EGFRm NSCLC - Ph3 - Topline (TROPION-Lung14)

ClinicalTrials.gov, AZN JPM 2026

Tezspire - EoE - Ph3 - Topline

AZN JPM 2026 Presentation

Imfinzi - Early HCC - Ph3 - Topline

AZN JPM 2026 Presentation

Xolair - Biosimilar Competition

Roche JPM 2026 Presentation

Giredestrant - Early BC - FDA/EMA Approval

Roche PR Dec 10, 2025 (lidERA positive)

Saphnelo - Lupus Nephritis - Ph3 - Topline

AZN JPM 2026 Presentation

Petosemtamab - HNSCC - Ph3 - Interim (LiGeR-HN2)

Genmab-Merus acquisition press release Sep 29, 2025; FDA BTD designations

Saphnelo - Systemic Sclerosis - Ph3 - Topline

AZN JPM 2026 Presentation

Petosemtamab - HNSCC - Ph3 - Interim (LiGeR-HN1)

FDA BTD designation; Genmab FY2025 earnings call Feb 17, 2026

Camizestrant - HR+ Breast - Ph3 - Topline (SERENA-4)

ClinicalTrials.gov NCT04711252, AZN JPM 2026

Wainua - ATTR-CM - Ph3 - Topline (CARDIO-TTRansform)

Ionis/AZN partnership, ClinicalTrials.gov

Rystiggo - MOG Antibody Disease - Ph3 - Headline Results

UCB Pipeline page (ucb.com/innovation/pipeline)

Epkinly - DLBCL - Ph3 - Topline (EPCORE DLBCL-2)

ClinicalTrials.gov NCT05578976

Bimzelx vs Risankizumab - PsA - Head-to-Head Data

UCB Pipeline page (ucb.com/innovation/pipeline)

Datroway + Imfinzi - 1L NSCLC - Ph3 - Topline (AVANZAR)

DSNKY Q3 FY2025 Earnings, ClinicalTrials.gov NCT05687266

ABBV-RGX-314 - Wet AMD - Ph3 - Data (ATMOSPHERE)

AbbVie Q4 2025 Earnings (news.abbvie.com)

Datroway + Keytruda - 1L NSCLC PD-L1 High - Ph3 - Topline (TROPION-Lung08)

DSNKY Q3 FY2025 Earnings, ClinicalTrials.gov NCT05215340

CagriSema - T2D - Ph3 - Data (REIMAGINE 3/4/5)

ClinicalTrials.gov REIMAGINE program, NVO pipeline

Tavapadon - Parkinson's - FDA Approval

AbbVie NDA submission Sep 2025 (news.abbvie.com)

Orforglipron - Obesity/T2D - EMA Approval

Lilly Q4 2025 Earnings

Sofetabart - PROC - Ph3 - Topline

Lilly Q4 2025 Earnings - BTD announcement

Taltz + Zepbound - PsA/Obesity - FDA Filing

Lilly Q4 2025 Earnings - positive Ph3 data

Zepbound - Medicare Part D Access

Lilly Q4 2025 Earnings (investor.lilly.com)

Zepbound vs CagriSema - Obesity - Ph3 - Topline (REDEFINE-4)

ClinicalTrials.gov REDEFINE-4 (NVO-sponsored)

Vyvgart - Myositis - Ph2/3 - Topline (ALKIVIA)

argenx Corporate Presentation Feb 2026

GS-3242 - HIV Treatment - Ph1 Data (Virology Conference)

Gilead Q4 2025 Earnings Presentation

Trodelvy - 1L HR+/HER2- mBC - Ph3 - OS Data (ASCENT-07)

Gilead Q4 2025 Earnings Presentation

Trodelvy - 1L mTNBC (non-CPI) - FDA Approval (ASCENT-03)

Gilead Q4 2025 Earnings Presentation

Trodelvy + Keytruda - 1L PD-L1+ mTNBC - FDA Approval (ASCENT-04)

Gilead Q4 2025 Earnings Presentation

Yescarta - 1L High-Risk LBCL - RMAT Data

Gilead Q4 2025 Earnings Presentation

Sunlenca + bNAbs - HIV Treatment - Ph3 Initiation

Gilead Q4 2025 Earnings Presentation

Claseprubart - MMN - Ph2 - Topline Data (MoMeNtum)

Dianthus Q3 2025 earnings release

Tezspire - COPD - Ph3 Data

Amgen Q4 2025 earnings

Fianlimab - Metastatic Melanoma 1L - Ph3 Topline (RELATIVITY-104)

REGN Q4 2025 earnings, regeneron.com/pipeline

Odronextamab - R/R FL - Ph3 Topline

REGN Q4 2025 earnings, regeneron.com/pipeline

Itepekimab - COPD - Ph3 Topline (AERIFY)

REGN Q4 2025 earnings, ClinicalTrials.gov

Pozelimab+Cemdisiran - gMG - Ph3 Topline (NIMBLE)

REGN Q4 2025 earnings, ClinicalTrials.gov

Lynozyfic - Earlier-line MM (2L-3L) - Ph3 Enrollment

REGN Q4 2025 earnings

CagriSema vs Zepbound - Obesity - Ph3 - Topline (REDEFINE-4)

ClinicalTrials.gov REDEFINE-4, NVO pipeline updates

Fianlimab - Adjuvant Melanoma - Ph3 Topline (RELATIVITY-106)

REGN Q4 2025 earnings, ClinicalTrials.gov

Vonjo - MF (severe thrombocytopenia) - Ph3 - Confirmatory (PACIFICA)

FDA post-marketing requirement; SOBI Pipeline page

Gamifant - IFN-gamma-driven Sepsis - Ph2b/3 Design Discussion

SOBI Q4 2025 Report; EMBRACE Phase 2a topline Jan 7, 2026

Tryngolza - Severe Hypertriglyceridemia - EMA Submission

SOBI Q4 2025 Report; Ionis pipeline updates

Ulotaront - Schizophrenia - Ph3 - Relapse Prevention (DIAMOND 5)

ClinicalTrials.gov; Otsuka pipeline update 2025

Ulefnersen - FUS-ALS - Ph3 - Topline (FUSION)

ClinicalTrials.gov NCT04768972; Ionis pipeline updates

Rina-S - PROC - Ph2 - Data Update (RAINFOL-01)

ClinicalTrials.gov NCT05579366

Epkinly - DLBCL - Ph3 - Topline (EPCORE DLBCL-2)

NCT05578976; EPCORE NHL-2 ASH 2024 (Blood 2024;144:581); POLARIX 5-year JCO 2025

Centanafadine - ADHD - FDA PDUFA Decision

Otsuka press release Jan 27, 2026; FDA PDUFA date

NVO - H1 2026 Results

novonordisk.com/investors/financial-calendar

TransCon CNP - Achondroplasia - EMA Decision

investors.ascendispharma.com JPM 2026 Presentation

Retatrutide - Obesity - NDA Submission

Analyst consensus based on TRIUMPH timeline

Orforglipron - Obesity - FDA Approval (Royalty)

Lilly Q4 2025 Earnings (partner asset)

Monlunabant - Obesity - Ph2b - Topline

NVO pipeline, Phase 2a PR Sep 2024

Vyvgart - ITP - Ph3 - Topline (ADVANCE-NEXT)

argenx Corporate Presentation Feb 2026

Empasiprubart - MMN - Ph3 - Topline

argenx Corporate Presentation Feb 2026

Vyvgart - AChR- gMG (Seronegative) - FDA Approval Decision

argenx Corporate Presentation Feb 2026

CagriSema - Obesity - FDA PDUFA

NVO NDA filing PR Dec 2025, standard 10-month review

Pozdeutinurad - Progressive Gout - Ph3 - Topline (REDUCE-1)

SOBI Q4 2025 Report

Tulisokibart - UC - Ph3 - Topline (ATLAS-UC)

ClinicalTrials.gov NCT06052059

Fabhalta - IgAN - Full Approval Data

ClinicalTrials.gov NCT04578834

CagriSema - Obesity CVOT - Ph3 - Updates (REDEFINE 3)

ClinicalTrials.gov NCT06246825

V940 - Melanoma - Ph3 - Interim (INTerpath-001)

Moderna/Merck PR Jan 20, 2026

Padsevonil - Drug-Resistant Epilepsy - Ph3 - Updates

UCB Pipeline page

R-DXd - Platinum-Resistant Ovarian - Ph2/3 - Updates (REJOICE-Ovarian01)

daiichisankyo.com ESMO 2025, ClinicalTrials.gov

Remibrutinib - Hidradenitis Suppurativa - Ph3 - Topline

Novartis JPM 2026 Pipeline

Bepranemab - PSP/Alzheimer's - Ph2 - Updates

UCB Pipeline page

Remibrutinib - CIndU - Ph3 - Topline

Novartis JPM 2026 Pipeline

Keytruda - LOE Preparation

Merck JPM 2026 (CEO Davis)

Islatravir - HIV - Ph3 - Updates

Merck JPM 2026 (CEO Davis)

Ianalumab - SLE - Ph3 - Topline (SIRIUS-SLE)

ClinicalTrials.gov, Novartis JPM 2026

ACCG-2671 - Obesity (Amylin) - Ph1 - Data

ir.structuretx.com, typical Ph1 timeline

LTSE-2578 - IPF - Ph2 Potential Start

ir.structuretx.com quarterly updates

Epkinly - DLBCL - Ph3 - Topline (EPCORE DLBCL-4)

Genmab JPM 2026 Presentation

Vyloy + Keytruda + Chemo - 1L Gastric - Ph3 - Updates (LUCERNA)

ClinicalTrials.gov NCT06901531, Astellas JPM 2026

Petosemtamab - HNSCC - BLA Filing

Genmab JPM 2026 Presentation

Rina-S - PROC - Accelerated Approval Filing

Genmab JPM 2026 Presentation

Divarasib - NSCLC - Ph3 - Topline (KRASCENDO-1)

ClinicalTrials.gov (PCD pushed to Sep 2027)

Prasinezumab - Parkinson's - Ph2b - Topline (PADOVA)

Roche JPM 2026 Presentation

Zilebesiran - Hypertension - Ph3 - Topline

Alnylam/Roche partnership

XTANDI - US Patent Expiration Preparation

Astellas JPM 2026 (CEO Okamura), Q3 FY2025 Earnings

Lixiana - Patent Expiration Preparation

DSNKY investor presentations

Datroway + Keytruda - 1L NSCLC PD-L1 Low - Ph3 - Topline (TROPION-Lung07)

DSNKY Q3 FY2025 Earnings, ClinicalTrials.gov NCT05555732

Cosentyx - Biosimilar Competition Timeline

Novartis investor presentations

Donanemab - Preclinical AD - Ph3 - Interim (TRAILBLAZER-ALZ 3)

Lilly Kisunla label update PR (investor.lilly.com)

MariTide - T2D + Obesity - Ph3 - Topline (MARITIME-2)

Amgen Q4 2025 earnings call (Feb 3, 2026)

IMDELLTRA - 1L ES-SCLC - Ph3 Data (DeLLphi-308/312)

Amgen Q4 2025 earnings

MariTide - Obesity - Ph3 - Topline (MARITIME-1)

Amgen Q4 2025 earnings call (Feb 3, 2026)

ALPMY - 30% Core OP Margin Target

Astellas JPM 2026 (CEO Okamura)

Repinatrabit - PKU - Ph3 - Topline (NCT06971731)

ClinicalTrials.gov NCT06971731; Otsuka press release Dec 2025

Riliprubart - CIDP (Refractory) - Ph3 - Primary Data (MOBILIZE)

ClinicalTrials.gov NCT06290128

Ianalumab - Sjogren's - Ph3 - Topline

Novartis JPM 2026 Pipeline

Pegozafermin - MASH - Ph3 - Topline

89bio partnership, ClinicalTrials.gov

Vyvgart - Sjogren's Disease - Ph3 - Topline

argenx Corporate Presentation Feb 2026

Empasiprubart - CIDP - Ph3 - Topline

argenx Corporate Presentation Feb 2026

MariTide - Obesity - BLA Filing

Amgen guidance, analyst consensus

Olpasiran - Elevated Lp(a) - OCEAN(a)-Outcomes CVOT

Amgen Q4 2025 earnings, ClinicalTrials.gov NCT05581303

Dapirolizumab Pegol - SLE - Ph3 - Topline (PHOENYCS FLY)

ClinicalTrials.gov NCT06617325, Biogen/UCB PR

Riliprubart - CIDP (vs IVIg) - Ph3 - Primary Data (VITALIZE)

ClinicalTrials.gov NCT06290141

MariTide - HFpEF - Ph3 - Outcomes (MARITIME-HF)

ClinicalTrials.gov NCT07037459